title: A Subgroup Analysis of Chinese Patients Switched to Paliperidone Palmitate One-Month Injectable by Prior Oral Antipsychotic Treatment.
abstract: BACKGROUND
  Safely tapering current antipsychotic medication, while balancing efficacy and tolerability, is an important consideration when switching patients from their antipsychotic therapy to a new treatment. The efficacy and tolerability of paliperidone palmitate one-month (PP1M) in Chinese patients switched from previous antipsychotic treatments were examined in order to develop effective switching and dosing strategies.
  
  
  METHODS
  A 13-week open-label, single arm, prospective, interventional study was conducted in Chinese patients (n = 610) with acute schizophrenia to examine their response, by previous treatment group, when switched to PP1M (75-150 mg eq).
  
  
  RESULTS
  Among 610 patients with ≥ 30% reduction in PANSS total score were 191/263 (72.6%) risperidone/paliperidone extended-release patients, 36/52 (69.2%) olanzapine patients, and 214/293 (73.0%) other antipsychotic patients. Patient functioning and adherence were significantly (p ≤ 0.05) improved for all subgroups.
  
  
  CONCLUSIONS
  Patients on higher doses of prior antipsychotics generally took longer to withdraw from their current medication. Most patients were administered the 100 mg eq dose, and all subgroups received a similar mean dose (114-119 mg eq) of PP1M. Recommendations for transitioning patients to PP1M from each subgroup are discussed.
authors.affiliation: Peking University Sixth Hospital/Institute of Mental Health, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: T
authors.initials: T
authors.lastname: Si
authors.affiliation: Nanjing Brain Hospital, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: J
authors.initials: J
authors.lastname: Fan
authors.affiliation: The First Hospital of Hebei Medical University, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.affiliation: Qingdao Mental Health Center, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.affiliation: Shantou University Mental Health Center, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.affiliation: Janssen Research & Development, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhuo
authors.affiliation: Janssen Research & Development, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), and the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Feng
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D044466:Asian People; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D057915:Drug Substitution / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D000068882:Paliperidone Palmitate / Q000008:administration & dosage*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D000068882:Paliperidone Palmitate